Use of monomycolyl glycerol (MMG) as an adjuvant
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Oct 22, 2013
Issued Date -
N/A
app pub date -
Jun 26, 2008
filing date -
Jun 29, 2007
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
Here we identify MMG and its alpha- and ketomycolic acid derivatives as highly bioactive lipids derived from M. bovis BCG (Copenhagen) capable of stimulating and activating human DC's at exceedingly low doses. In addition to their direct role as immunostimulators of human DC's we demonstrate their use in the development of a new generation of adjuvants suitable for human administration. We furthermore identify a number of highly active synthetic MMG analogues with great potential in cancer treatment, and for vaccine adjuvants against both infectious disease and disorders like Alzheimers disease.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully